A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

December 17, 2008

Tesamorelin Diminished Gut Fat in Phase 3 Study

The Canadian company Theratechnologies announced Monday that its experimental drug tesamorelin reduced belly fat accumulation by 18 percent over 52 weeks in the second of two Phase 3 clinical trials. And in a second announcement on Tuesday, the company confirmed a proposed deal with EMD Serono to sell the drug in the United States once it is approved.

Tesamorelin prompts the pituitary gland to release more growth hormone into the body and promotes fat loss.

The most recent Phase 3 clinical trial was similar in design to a previous study reported by the company. HIV-positive participants with gut-fat accumulation received either a placebo or tesamorelin for 26 weeks. At that point, people who had taken the placebo switched to tesamorelin and those who had taken the drug either stayed on it or switched to a placebo for an additional 26 weeks. After the first 26 week portion of the trial, people on tesamorelin lost 11 percent of their gut fat; those who remained on the drug for a full 52 weeks ultimately lost 18 percent. The drug appears not to interfere with the body’s development of insulin and control of blood sugar, a problem with EMD Serono’s Serostim (recombinant human growth hormone), another product studied to treat gut-fat accumulation in people with HIV.

In its deal with EMD Serono, Theratechnologies received a $30 million up-front payment. In return, EMD Serono will assist Theratechnologies with its application to the U.S. Food and Drug Administration for tesamorelin’s approval. Serono EMD will also sell the drug in the United States. Theratechnologies stands to gain as much as $215 million from the deal in addition to further royalties from future U.S. sales of the drug.

Search: Theratechnologies, tesamorelin, EMD Serono, lipodystrophy, fat accumulation, gut, Phase 3, growth hormone, Serostim


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dambitious
    Gone
    New York


    slimcuteguy
    Asheville
    North Carolina


    ernienyc
    Bronx
    New York


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.